Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04671251
Recruitment Status : Completed
First Posted : December 17, 2020
Last Update Posted : May 4, 2022
Information provided by (Responsible Party):
Avalo Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : March 30, 2022
Actual Study Completion Date : March 30, 2022
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 September 27, 2022